Scholar Rock Holding - Biotech Company with a Promising Pipeline - Approval of Apitegromab Should Drive Results Sustainably!

Business drivers: Scholar Rock Holding Corp. (SRRK) is a US biotech company focused on developing new therapies for the treatment of rare diseases. One of the most promising product candidates in the pipeline is Apitegromab, a potential drug for the treatment of Spinal Muscular Atrophy (SMA). Recently, Scholar Rock Holding completed a bond placement of $200 million to secure further funding for a possible product launch of Apitegromab, for which positive Phase III clinical trial data was recently presented. As Scholar Rock announced during...